ATXS — Astria Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $291.76m
- $58.96m
- 28
- 29
- 41
- 23
Annual income statement for Astria Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 37.4 | 195 | 53.5 | 83 | 112 |
| Operating Profit | -37.4 | -195 | -53.5 | -83 | -112 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -37.3 | -195 | -51.8 | -72.9 | -94.3 |
| Net Income After Taxes | -37.3 | -195 | -51.8 | -72.9 | -94.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -37.3 | -195 | -51.8 | -72.9 | -94.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.3 | -219 | -51.8 | -72.9 | -94.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -12.2 | -24.6 | -3.55 | -2.42 | -1.68 |